Camellia Vermillion
Psychiatric/Mental Health · Poplar Bluff, MONPI 1275752354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,771, 3.0 times the $594 reported in 2021.
Across 240 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$719
- Alkermes, Inc.$484
- Otsuka America Pharmaceutical, Inc.$484
- Neurocrine Biosciences, Inc.$384
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$379
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,19693%
- Education$3617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,175 |
| Teva Pharmaceuticals USA, Inc. | 18 | $719 |
| Alkermes, Inc. | 25 | $484 |
| Otsuka America Pharmaceutical, Inc. | 9 | $484 |
| Neurocrine Biosciences, Inc. | 27 | $384 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $379 |
| Johnson & Johnson | 9 | $373 |
| Astellas Pharma US Inc | 5 | $201 |
| Vanda Pharmaceuticals Inc. | 7 | $183 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $156 |
| Axsome Therapeutics, Inc. | 2 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Myovant Sciences Inc. | 4 | $68 |
| Lilly USA, LLC | 4 | $60 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Amgen | 4 | $56 |
| Merck | 4 | $55 |
| Exeltis, USA Inc. | 3 | $53 |
| Corium, LLC | 3 | $51 |
| Eisai Inc. | 4 | $48 |
| Indivior Inc. | 2 | $47 |
| Mayne Pharma Commercial LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Evofem Biosciences, Inc. | 2 | $30 |
| AstraZeneca | 2 | $27 |
| Roche Diagnostics Corporation | 1 | $26 |
| Virtus Pharmaceuticals LLC | 2 | $26 |
| Novo Nordisk | 1 | $19 |
| Organon | 2 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$460
- INVEGA SUSTENNA$243
- CAPLYTA$241
- ABILIFY ASIMTUFII$240
- ABILIFY MAINTENA$240
- Austedo XR$240
- UZEDY$231
- INGREZZA$134
- VRAYLAR$123
- Auvelity$120
- REXULTI$119
- Fanapt$114
How this compares
$5,557 in reported general payments places this provider in the 85th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $54,140 |
| PerserisRisperidone | 14 | $38,280 |
| VraylarCariprazine Hcl | 20 | $29,521 |
| Lurasidone Hcl | 64 | $14,824 |
| Chlorpromazine Hcl | 27 | $7,614 |
| Aripiprazole | 77 | $3,767 |
| Buspirone Hcl | 172 | $3,676 |
| Clozapine | 12 | $2,991 |
| Oxcarbazepine | 69 | $2,963 |
| Risperidone | 125 | $2,467 |
| Quetiapine Fumarate | 113 | $2,282 |
| Fluoxetine Hcl | 121 | $1,606 |
| Mirtazapine | 70 | $1,464 |
| Bupropion Hcl | 29 | $1,413 |
| Hydroxyzine Hcl | 95 | $1,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $373 | $54,14017 claims |
| Indivior Inc.Perseris | $47 | $38,28014 claims |
| AbbVieVraylar | $1,175 | $29,52120 claims |
| Lilly USA, LLCOlanzapine | $60 | $94640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Poplar Bluff
- Kristerpher BrimberryPoplar Bluff$74K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.